Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May 31:8:669509.
doi: 10.3389/fmed.2021.669509. eCollection 2021.

Integrating Real-World Evidence in the Regulatory Decision-Making Process: A Systematic Analysis of Experiences in the US, EU, and China Using a Logic Model

Meng Li  1 , Shengqi Chen  1 , Yunfeng Lai  1 , Zuanji Liang  1 , Jiaqi Wang  1 , Junnan Shi  1 , Haojie Lin  1 , Dongning Yao  1 , Hao Hu  1 , Carolina Oi Lam Ung  1
Affiliations

Integrating Real-World Evidence in the Regulatory Decision-Making Process: A Systematic Analysis of Experiences in the US, EU, and China Using a Logic Model

Meng Li et al. Front Med (Lausanne). .

Abstract

Real world evidence (RWE) and real-world data (RWD) are drawing ever-increasing attention in the pharmaceutical industry and drug regulatory authorities (DRAs) all over the world due to their paramount role in supporting drug development and regulatory decision making. However, there is little systematic documentary analysis about how RWE was integrated for the use by the DRAs in evaluating new treatment approaches and monitoring post-market safety. This study aimed to analyze and discuss the integration of RWE into regulatory decision-making process from the perspective of DRAs. Different development strategies to develop and adopt RWE by the DRAs in the US, Europe, and China were reviewed and compared, and the challenges encountered were discussed. It was found that different strategies on development of RWE were applied by FDA, EMA, and NMPA. The extent to which RWE was adopted in China was relatively limited compared to that in the US and EU, which was highly related to the national pharmaceutical environment and development stages. A better understanding of the overall goals, inputs, activities, outputs, and outcomes in developing RWE will help inform actions to harness RWD and leverage RWE for better health care decisions.

Keywords: decision-making; logic model; real-world evidence; regulation; regulatory science.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

    1. Jarow JP, LaVange L, Woodcock J. Multidimensional evidence generation and FDA regulatory decision making: defining and using “real-world” data. JAMA. (2017) 318:703–4. 10.1001/jama.2017.9991 - DOI - PubMed
    1. Perfetto EM, Oehrlein EM, Anyanwu C, Burcu M, Gaitonde P, Hanna ML, et al. Maryland Center of Excellence in Regulatory Science and Innovation (M-CERSI) Conference 2015: Patient-Focused Drug Development (PFDD) University of Maryland Baltimore (2015).
    1. Liu Q, Ramamoorthy A, Huang SM. Real-world data and clinical pharmacology: a regulatory science perspective. Clin Pharmacol Ther. (2019) 106:67–71. 10.1002/cpt.1413 - DOI - PubMed
    1. Suvarna VR. Real world evidence (RWE)-Are we (RWE) ready? Perspect Clin Res. (2018) 9:61. 10.4103/picr.PICR_36_18 - DOI - PMC - PubMed
    1. Rath A, Salamon V, Peixoto S, Hivert V, Laville M, Segrestin B, et al. A systematic literature review of evidence-based clinical practice for rare diseases: what are the perceived and real barriers for improving the evidence and how can they be overcome? Trials. (2017) 18:556. 10.1186/s13063-017-2287-7 - DOI - PMC - PubMed